Summary of Q&A for Results Briefing of Fiscal Year 2020 held on May 21, 2021
May 21, 2021
You are aiming for a dividend payout ratio of 30% in the future, but please tell us when you can achieve it.
Regarding the capital investment, you mentioned that it was a level of over 80 billion yen during the period of the previous medium-term business plan. Please tell us whether you are planning to make a larger investment than the previous medium-term business plan in the next, or whether it will be compacter.
Please tell us what you can do to achieve a strong aquaculture business, and how you can achieve it in the face of high volatility due to the fishery market conditions.
In the FY2021 plan for the South American salmon/trout farming business, the contribution to the increase in profits will be 400 million yen. I think this is due to an increase in landing volume, an increase in factory productivity, etc., but please tell us how you are looking at the premise of demand, and whether you are looking at the premise that fish prices will not return significantly.
Regarding domestic aquaculture, with the possibility that domestic demand will return in the future, what kind of efforts will be made in the aquaculture business to meet the demand? Please tell us if you can respond flexibly to demand.
Regarding the Food Products Business, you commented that the cost of raw materials such as surimi was rising. What do you think about the possibility of price increases in Japan and overseas?
McDonald's is developing putty using meat substitutes in the United States. Can you handle it if there is a need from a major global fast-food company, not only in the United States but also in Asia?
Regarding the Food Products Business, the subsidiary Delmar is scheduled to be merged in July. Will the relationship be strengthened as a group? Please tell us what you think about the Asian strategy of the Food Products Business.
Please tell us if the increase in profit of 600 million yen in the FY2021 plan for the Fine Chemicals Business is expected to export pharmaceutical raw materials overseas.